Enhanced formation of non-phenolic androgen metabolites with instrisic oestrogen-like gene transactivation potency in human breast cancer cells: A distinctive metabolic pattern

Journal of Endocrinology

Volumn 190, Issue 3, 2006, Pages 805-818

  Pérez Palacios, Gregorio ^a   Santillán, René ^a,b   García Becerra, Rocío ^b   Borja Cacho, Elizabeth ^b   Larrea, Fernando ^b   Damián Matsumura, Pablo ^c   González, Leticia ^c   Lemus, Ana Elena ^c  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^c DEPARTAMENTO DE QUÍMICA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

3BETA ANDROSTANEDIOL; ANDROGEN; ANDROSTANEDIOL; ANDROSTANOLONE; ANDROSTENEDIONE; CARBON 14; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FINASTERIDE; FULVESTRANT; STEROID 5ALPHA REDUCTASE; TESTOSTERONE;

ANDROGEN METABOLISM; ANDROGEN SYNTHESIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL CULTURE; CELL PROLIFERATION; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; ESTROGEN ACTIVITY; EXPRESSION VECTOR; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HELA CELL; HORMONE ACTION; HORMONE METABOLISM; HUMAN; HUMAN CELL; INCUBATION TIME; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TESTOSTERONE METABOLISM; TRANSACTIVATION; YEAST CELL;

ANALYSIS OF VARIANCE; ANDROGENS; ANDROSTANE-3,17-DIOL; ANDROSTENEDIONE; BREAST NEOPLASMS; CARBON ISOTOPES; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGENS; FEMALE; GENE EXPRESSION PROFILING; HELA CELLS; HUMANS; ISOTOPE LABELING; TESTOSTERONE; TRANS-ACTIVATION (GENETICS); TRANSCRIPTIONAL ACTIVATION; TRANSFECTION;

EID: 33749990827     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.1.06407     Document Type: Article

References (75)

1. Adams JB 1998 Adrenal androgens and human breast cancer: a new appraisal. Breast Cancer Research and Treatment 51 183-188.
2. Ariga N, Moriya T, Suzuki T, Kimura M, Ohuchi N, Satomi S & Sasano H 2000 17β-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast. Anticancer Research 20 1101-1108.
3. Aspinall SR, Stamp S, Davison A, Shenton BK & Lennard TWJ 2004 The proliferative effects of 5-androstene-3β, 17β-diol and 5α-dihydrotestosterone on cell cycle analysis and cell proliferation in MCF7, T47D and MDAMB231 breast cancer cell lines. Journal of Steroid Biochemistry and Molecular Biology 88 37-51.
4. Bonney RC, Reed MJ, Davidson K, Beranek PA & James VH 1983 The relationship between 17 beta-hydroxysteroid dehydrogenase activity and oestrogen concentrations in human breast tumours and in normal breast tissue. Clinical Endocrinology 19 727-739.
5. Bradford MM 1976 A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 72 248-254.
6. Brodie AM & Longcope C 1980 Inhibition of peripheral aromatization by aromatase inhibitors, 4-hydroxy- and 4-acetoxy-androstene-3,17-dione. Endocrinology 106 19-21.
7. Brodie AM, Schwarzel WC, Shaikh AA & Brodie HJ 1977 The effect of an aromatase inhibitor, 4-hydroxy-4-androstene-3,17-dione, on estrogen-dependent processes in reproduction and breast cancer. Endocrinology 100 1684-1695.
8. Brueggemeier RW, Hackett JC & Diaz-Cruz ES 2005 Aromatase inhibitors in the treatment of breast cancer. Endocrine Reviews 26 331-345.
9. Buzdar AU 2002 New generation aromatase inhibitors-from the advanced to the adjuvant setting. Breast Cancer Research and Treatment 75 S13-S17.
10. Catherino, WH, Jeng MH & Jordan VC 1993 Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism. British Journal of Cancer 67 945-952.
11. 50) of an enzymatic reaction. Biochemical Pharmacology 22 3099-3108.
12. Coombes RC, Goss P, Dowsett M, Gazet JC & Brodie A 1984 4-Hydroxy androstenedione in treatment of postmenopausal patients with advanced breast cancer. Lancet 2 1237-1239.
13. Coombes RC, Goss PE, Dowsett M, Hutchinson G, Cunningham D, Jarman M & Brodie AMH 1987 4-Hydroxyandrostenedione treatment for postmenopausal patients with advanced breast cancer. Steroids 50 245-252.
14. Costlow ME, Buschow RA & McGuire WL 1976 Prolactin receptors and androgen-induced regression of 7,12-dimethylbenz(a)anthracene induced mammary carcinoma. Cancer Research 36 3324-3329.
15. Demers LM 1994 Effects of fadrozole (CGS 16949A) and letrozole (CGS20267) on the inhibition of aromatase activity in breast cancer patients. Breast Cancer Research and Treatment 30 95-102.
16. García-Becerra R, Borja-Cacho E, Cooney AJ, Jackson KJ, Lemus AE, Pérez-Palacios G & Larrea F 2002 The intrinsic transcriptional estrogenic activity of a non-phenolic derivative of levonorgestrel is mediated via the estrogen receptor-α. Journal of Steroid Biochemistry and Molecular Biology 82 333-341.
17. 4 isomerase type 1 gene transcription in human breast cancer cell lines and in normal mammary epithelial cells by interleukin-4 and interleukin-13. Molecular Endocrinology 13 66-81.
18. Girdler F & Brotherick I 2000 The oestrogen receptors (ERα and ERβ) and their role in breast cancer: a review. Breast 9 194-200.
19. Goss PE 1999 Risks versus benefits in the clinical application of aromatase inhibitors. Endocrine-Related Cancer 6 325-332.
20. Greeve MA, Allan RK, Harvey JM & Bemel JM 2004 Inhibition of MCF-7 breast cancer cell proliferation by 5alpha-dihydrotestosterone; a role for p21 (Cip1/Waf1). Journal of Molecular Endocrinology 32 793-810.
21. Hackenberg R, Turgetto I, Filmer A & Schulz KD 1993 Estrogen and androgen receptor mediated stimulation and inhibition of proliferation by androst-5-ene-3β, 17β-diol in human mammary cancer cells. Journal of Steroid Biochemistry and Molecular Biology 46 597-603.
22. Ishikawa T, Glidewell-Kenney C & Jameson JL 2006 Aromatase-independent testosterone conversion into estrogenic steroids is inhibited by a 5α-reductase inhibitor. Journal of Steroid Biochemistry and Molecular Biology 98 133-138.
23. Jørgensen L, Brünner N, Spang-Thomsen M, James MR, Clarke R, Dombernowsky P & Svenstrup B 1997 Steroid metabolism in the hormone dependent MCF-7 human breast carcinoma cell line and its two hormone resistant subpopulations MCF-7/LCC1 and MCF-7/LCC2. Journal of Steroid Biochemistry and Molecular Biology 63 275-281.
24. Kirschner MA 1979 The role of hormones in the development of human breast cancer. In Breast Cancer 3: Advances in Research and Treatment, Current Topics., New York: Plenum Press. pp 199-229.
25. Kubli-Garfias C, Vázquez R & Mendieta J 1998 Austin model 1 study of the effect of carbonyl and hydroxyl functional groups on the electronic structure of androstane. Journal of Molecular Structure (Theochem) 428 189-194.
26. Kubh-Garfias C, Vázquez R, Cooney AJ & Larrea F 2002 Ab initio electronic structure of the progestogen norethisterone and its 5α-derivatives. Journal of Steroid Biochemistry and Molecular Biology 82 385-391.
27. Labrie F, Simard J, de Launoit Y, Poulin R, Theriault C, Dumont M, Dauvois S, Martel C & Li S-M 1992 Androgens and breast cancer. Cancer Detection and Prevention 16 31-38.
28. Labrie F, Luu-The V, Lin S-X, Labrie C, Simard J, Breton R & Bélanger A 1997 The key role of 17β-hydroxysteroid dehydrogenases in sex steroid biology. Steroids 62 148-158.
29. Labrie F, Bélanger A, Luu-The V, Labrie C, Simard J, Cusan L, Gomez J-L & Candas B 1998 DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: its role during aging. Steroids 63 322-328.
30. Labrie F, Luu-The V, Lin SX, Simard J, Labrie C, El-Alfy M, Pelletier G & Bélanger A 2000 Intracrinology: role of the family of 17β-hydroxysteroid dehydrogenases in human physiology and disease. Journal of Molecular Endocrinology 25 1-16.
31. Labrie F, Luu-The V, Labrie C, Bélanger A, Simard J, Lin S-X & Pelletier G 2003 Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocrine Reviews 24 152-182.
32. Larrea F, García-Becerra R, Lemus AE, García GA, Pérez-Palacios G, Jackson KJ, Coleman KM, Dace R, Smith CL & Cooney AJ 2001 A-ring reduced metabolites of 19-nor synthetic progestins as subtype selective agonists for ERα. Endocrinology 142 3791-3799.
33. Lemus AE, Zaga V, Santillán R, García GA, Grillasca I, Damián-Matsumura P, Jackson KJ, Cooney AJ, Larrea F & Pérez-Palacios G 2000 The oestrogenic effects of gestodene, a potent contraceptive progestin, are mediated by its A-ring reduced metabolites. Journal of Endocrinology 165 693-702.
34. Lemus AE, Santillán R, Damián-Matsumura P, García GA, Grillasca I & Pérez-Palacios G 2001 In vitro metabolism of gestodene in target organs: formation of A-ring reduced derivatives with oestrogenic activity. European Journal of Pharmacology 417 249-256.
35. Liao DJ & Dickson RB 2002 Roles of androgens in the development, growth, and carcinogenesis of the mammary gland. Journal of Steroid Biochemistry and Molecular Biology 80 175-189.
36. Liao D-ZJ, Cooley GP, Pantazis CG, Hou X & Li SA 1998 Promotion of estrogen induced mammary gland carcinogenesis by androgen in the male Noble rat: probable mediation by steroid receptors. Carcinogenesis 19 2173-2180.
37. Lippman M 1998 Endocrine-responsive cancer. In Williams Textbook of Endocrinology, pp 1675-1692. Eds JD Wilson, DW Foster, HM Kronenberg & PR Larsen. Philadelphia, PA: W.B. Saunders Company.
38. Lippman M, Bolan G & Huff K 1976 The effects of androgens and antidrogens on hormone responsive human breast cancer in long-term tissue culture. Cancer Research 36 4610-4618.
39. Lønning PE 2004 Aromatase inhibitors in breast cancer. Endocrine-Related Cancer 11 179-189.
40. Lopez-Diazguerrero, NE, Lopez-Araiza K Conde-Perezprina JC, Bucio L, Cardenas-Aguayo MC, Ventura JL, Covarrubias L, Gutierrez-Ruiz MC, Zentella A & Konigsberg M 2006 Bcl-2 protects against oxidative stress while inducing premature senescence. Free Radical Biology and Medicine 40 1161-1169.
41. Maggiolini M, Donzé O, Jeannin E, Andò S & Picard D 1999 Adrenal androgens stimulate the proliferation of breast cancer cells as direct activators of estrogen receptor α. Cancer Research 59 4864-4869.
42. Musgrove EA & Sutherland RL 1994 Cell cycle control by steroid hormones. Seminars in Cancer Biology 5 381-389.
43. Nicholson RI, Gotting KE, Gee J & Walker KJ 1988 Actions of oestrogens and antioestrogens on rat mammary gland development: relevance to breast cancer prevention. Journal of Steroid Biochemistry 30 95-103.
44. Pasqualini JR & Chetrite G 1996 Activity, regulation and expression of sulfatase, sulfotransferase, and 17β-hydroxysteroid dehydrogenase in breast cancer. In Hormone-Dependent Cancer, pp 25-80. Eds JR Pasqualini & BS Katzenellenbogen. New York, NY, USA: Marcel Dekker, Inc.
45. Pike MC & Spicer DV 1991 Endogenous estrogen and progesterone as the major determinants of breast cancer risk: prospects for control by "natural" and "technological" means. In Hormonal Carcinogenesis, pp 209-216. Eds JJ Li, S Nandi & SA Li. New York, NY, USA: Springer-Verlag.
46. Pike MC, Spicer DV, Dahmoush L & Press MF 1993 Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiologic Reviews 15 17-35.
47. Poulin R, Baker D & Labrie F 1988 Androgens inhibit basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line. Breast Cancer Research and Treatment 12 213-225.
48. Ragaz J 1999 Status of aromatase inhibitors in relation to other breast cancer treatment modalities. Endocrine-Related Cancer 6 277-291.
49. Reel JR, Humphrey RR, Shih Y-H, Windsor BL, Sakowski R, Creger PL & Edgren RA 1979 Competitive progesterone, antagonists: receptor binding and biological activity of testosterone and 19-nortestosterone derivatives. Fertility and Sterility 31 552-561.
50. Roy R, Dauvois S, Labrie F & Bélanger A 1992 Estrogen-stimulated glucuronidation of dihydrotestosterone in MCF-7 human breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology 41 579-582.
51. Russell DW & Wilson JD 1994 Steroid 5α-reductase: two genes/two enzymes. Annual Review of Biochemistry 63 25-61.
52. Santen RJ, Manni A, Harvey H & Redmond C 1990 Endocrine treatment of breast cancer in women. Endocrine Reviews 11 221-265.
53. Santillán R, Pérez-Palacios G, Reyes M, Damián-Matsumura P, García GA, Grillasca I & Lemus AE 2001 Assessment of the oestrogenic activity of the contraceptive progestin levonorgestrel and its non-phenolic metabolites. European Journal of Pharmacology 427 167-174.
54. Sasano H, Frost AR, Saitoh R, Harada N, Poutanen M, Vihko R, Bulun SE, Silverberg SG & Nagura H 1996 Aromatase and 17β-hydroxysteroid dehydrogenase type 1 in human breast carcinoma. Journal of Clinical Endocrinology and Metabolism 81 4042-4046.
55. Sasano H, Sato S, Ito Y, Yajima A, Nakamura J, Yoshihama M, Ariga K, Anderson TJ & Miller WR 1999 Effects of aromatase inhibitors on the pathobiology of human breast, endometrial and ovarian carcinoma. Endocrine-Related Cancer 6 197-204.
56. Schoonen WGEJ, Joosten JWH & Kloosterboer HJ 1995a Effects of two classes of progestagens, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells: II, T47D cell lines. Journal of Steroid Biochemistry and Molecular Biology 55 423-437.
57. Schoonen WGEJ, Joosten JWH & Kloosterboer HJ 1995b Efrects of two classes of progestagens, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells: II, T47D cell lines. Journal of Steroid Biochemistry and Molecular Biology 55 439-444.
58. Smith JA & King RJ 1972 Effects of steroids on growth of an androgen-dependent mouse mammary carcinoma in cell culture. Experimental Cell Research 73 351-359.
59. Smith CL, Conneely OM & O'Malley BW 1993 Modulation of the ligand-independent activation of the human estrogen receptor by hormone and antihormone. PNAS 90 6120-6124.
60. Somboonporn W & Davis SR 2004 Testosterone e&cts on the breast: implications for testosterone therapy for women. Endocrine Reviews 25 374-388.
61. Sonne-Hansen K & Lykkesfeldt AE 2005 Endogenous aromatization of testosterone results in growth stimulation of the human MCF-7 breast cancer cell line. Journal of Steroid Biochemistry and Molecular Biology 93 25-34.
62. Steckelbroeck S, Jin Y, Gopishetty S, Oyesamni B & Penning TM 2004 Human cytosolic 3α-hydroxysteroid dehydrogenases of the aldo-keto reductase superfamily display significant 3β-hydroxysteroid dehydrogenase activity. Journal of Biological Chemistry 279 10784-10795.
63. Suzuki T, Moriya T, Ariga N, Kaneko C, Kanazawa M & Sasano H 2000 17β-Hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parameters. British Journal of Cancer 82 518-523.
64. Suzuki T, Darnel AD, Akahira J-I, Ariga N, Ogawa S, Kaneko C, Takeyama J, Moriya T & Sasano, H 2001 5α-Reductases in human breast carcinoma: possible modulator of in situ androgenic actions. Journal of Clinical Endocrinology and Metabolism 86 2250-2257.
65. Suzuki T, Miki Y, Nakamura Y, Moriya T, Ito K, Ohuchi N & Sasano H 2005 Sex steroid producing enzymes in human breast cancer. Endocrine-Related Cancer 12 701-720.
66. Szelei J, Jimenez J, Soto AM, Luizzi MF & Sonnenschein C 1997 Androgen-induced inhibition of proliferation in human breast cancer MCF7 cells transfected with androgen receptor. Endocrinology 138 1406-1412.
67. Weihua Z, Mäkelä S, Andersson LC, Salmi S, Saji S, Webster JI, Jensen EV, Nilsson S, Warner M & Gustafsson J-Å 2001 A role for estrogen receptor β in the regulation of growth ofthe ventral prostate. PNAS 98 6330-6335.
68. Weihua Z, Lathe R, Warner M & Gustafsson J-Å 2002 An endocrine pathway in the prostate, ERβ, AR, 5α-androstane-3β,17β-diol, and CYP7B1, regulates prostate growth. PNAS 99 13589-13594.
69. Weiler PJ & Wiebe JP 2000 Plasma membrane receptors for the cancer-regulating progesterone metabolites, 5α-pregnane-3,20-dione and 3α-hydroxy-4-pregnen-20-one in MCF-7 breast cancer cells. Biochemical and Biophysical Research Communications 272 731-737.
70. Wiebe JP & Muzia D 2001 The endogenous progesterone metabolite, 5α-pregnane-3, 20-dione, decreases cell-substrate attachment, adhesion plaques, vinculin expression, and polymerized F-actin in MCF-7 breast cancer cells. Endocrine 16 7-14.
71. Wiebe JP & Lewis MJ 2003 Activity and expression of progesterone metabolizing 5α-reductase, 20α-hydroxysteroid oxidoreductase and 3α(β)-hydroxysteroid oxidoreductases in tumorigenic (MCF-7, MDA-MB-231, T-47D) and nontamorigenic (MCF-10A) human breast cancer cells. BMC Cancer 3 1-15.
72. Wiebe JP, Muzia D, Hu J, Szwajcer D, Hill SA & Seachrist JL 2000 The 4-pregnene and 5α-pregnane progesterone metabolites formed in nontumorous and tumorous breast tissue have opposite effects on breast cell proliferation and adhesion. Cancer Research 60 936-943.
73. Wing LY, Garrett WM & Brodie AM 1985 Effects of aromatase inhibitors, aminoglutethimide, and 4-hydroxyandrostenedione on cyclic rats and rats with 7,12-dimethylbenz(a)anthraceneinduced mammary tumors. Cancer Research 45 2425-2428.
74. Xie B, Tsao, SW & Wong YC 1999 Sex hormone-induced mammary carcinogenesis in female Noble rats: the role ofandrogens. Carcinogenesis 20 1597-1606.
75. Zhou J, Ng S, Adesanya-Famuiya O, Anderson K & Bondy CA 2000 Testosterone inhibits estrogen-induced mammary epithelial proliferation and suppresses estrogen receptor expression. FASEB Journal 14 1725-1730.